Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Natura: Artigo
Lingua:Inglês
Pubblicazione: NIHR Journals Library 2010-01-01
Serie:Health Technology Assessment
Soggetti:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Accesso online:https://doi.org/10.3310/hta14020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi